Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeOSSIOOSSIOfiber Trimmable Fixation Nail System Launches in the U.S.

OSSIOfiber Trimmable Fixation Nail System Launches in the U.S.

For Broad Utilization in Foot/Ankle and Hand/Wrist Procedures New Biointegrative System Offers Screw-Like Stability with the Utility of a Trimmable Nail, Leaving No Permanent Implant Behind

July 22, 2020

OSSIOfiber Trimmable Fixation Nail System official US launch and first commercial use, to securely fixate bone fractures, osteotomies and arthrodeses for healing, ultimately leaving the patient’s bone restored with no permanent hardware left behind was announced today by Ossio, Inc. The first commercial cases were bunion and MTP fusion procedures performed successfully by Chris Hyer, DPM, Foot and Ankle Surgeon at Polaris Surgery Center in Westerville, Ohio.

Part of the OSSIOfiber Bone Pin Product Family, which received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) in 2019, the OSSIOfiber® Trimmable Fixation Nail System includes strong, biointegrative Trimmable Fixation Nails in 2.4mm and 4.0mm diameters packaged with corresponding sterile, disposable instrumentation. These trimmable nails rival the performance of metal compression screws, combining the necessary strength for bone fixation with the ability to provide rapid bone in-growth, regeneration, and replacement without adverse inflammation, therefore avoiding the costs, pain, and complications often seen with permanent hardware.

Additionally, the ability to trim the implants to any desired length enables customization to any patient anatomy and adaptability for a wide range of surgical indications including forefoot, midfoot, hindfoot, and an array of hand/wrist applications.

“Having successfully utilized this new biointegrative option in my own clinical practice, it is clear that the OSSIOfiber® Trimmable Fixation Nails have real potential to replace metal compression screws and pins in numerous orthopedic procedures, with the ability to optimize bone healing while avoiding permanent implant-related post-operative complications,” said Dr. Hyer. “This novel trimmable nail system is exceptionally strong and well-designed, providing both the stability needed for solid fixation, natural healing and integration into the surrounding anatomy. The ease-of-use of the pre-sterilized, disposable instrumentation is excellent, and I like how the tapered ends of the nail allow for straightforward insertion into the bone tunnel and that it can be easily trimmed for broad procedural utility.”

OSSIO’s proprietary OSSIOfiber technology is engineered from a high performing matrix of reinforcing mineral fibers yielding strength that is 1.5 times greater than cortical bone. The design features of the OSSIOfiber® Trimmable Fixation Nail System contribute to the ability to maintain compression, stability and fixation strength and strong pull-out strength. Additionally, the hexagonal shape of the trimmable nails resist rotation, which prevents loosening that often results in screw back-out.

Additional procedures utilizing the OSSIOfiber® Trimmable Fixation Nail System are planned across the United States in the coming weeks.

“We are pleased to bring our next biointegrative fixation system to market, providing surgeons and their patients with an alternative to metal screws and pins that deliver strength, stability and utility for multiple surgical applications – all while fully integrating into the patient’s bone and leaving nothing permanent behind,” said Brian Verrier, CEO, OSSIO. “Adoption of our OSSIOfiber® Bone Pin Family has been strong to date, with substantial customer utilization across the U.S. We look forward to bringing additional breakthrough technology platforms to market that utilize our proprietary OSSIOfiber® technology and deliver a new standard of care in orthopedic fixation.”

Earlier this year, the company received FDA 510(k) Clearance for its OSSIOfiber® Hammertoe Fixation System. Approximately 700 hammertoe repairs have been conducted to date utilizing the implant.

“OSSIO continues to add promising, innovative solutions that offer an alternative to metal implants to our surgical toolbox,” said Erik Carlson, MD, Hand and Upper Extremity Specialist, Active Orthopaedics PC, and Chief of Orthopaedic Surgery, St. Mary’s Hospital, Waterbury CT. “OSSIOfiber® technology has a strong performance track-record and continues to demonstrate excellent clinical outcomes in the foot and ankle space, with high surgeon and patient satisfaction across the board. I look forward to actively utilizing the customizable OSSIOfiber Trimmable Fixation Nail System in applicable hand and wrist procedures.”

OSSIOfiber® Intelligent Bone Regeneration Technology can address many surgical applications through the manufacturing of endless implant designs, including nails, screws, anchors and plates. The company intends to pursue multiple applications in the distal extremity, trauma, sports, reconstruction, pediatrics and spine segments.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy